BUXORO VILOYATIDA COVID-19 KASALLIGI TARQALISHIDA AHOLI HUDUDIY TAQSIMLANISHINING TUTGAN O’RNI
Abstract
Mavzuning dolzarbligi: COVID-19 kasalligi qoʻzgʻatuvchisi boʻlgan ogʻir
oʻtkir respirator koronavirus infeksiyasining (SARS-CoV-2) ning tez suratda
tarqalishi, bu kasallik to’g’risidagi nafaqat klinik ma’lumotlarni , balki kasallikning
ijtimoiy xususiyatlarini ham aniqlash zarurligini ko’rsatdi. Butun dunyo bo’ylab
izlanishlar jarayonida COVID-19 kasalligining juda ko’plab ijtimoiy xususiyatlari
aniqlandi. O’z navbatida olib borilgan tadqiqodlar tahlili orqali kasallikning
tarqalishida aholining hududiy ya’ni territorial taqsimlanishining tutgan o’rni juda
muhim ahamiyatga ega ekanligini ko’rish mumkin. Bu tadqiqodda bemorlarning
shahar yoki qishloq aholisiga mansubligi, COVID-19 kasalligining ma’lum bir
regiyonda qanday darajada tarqalganligini va tarqalish xususiyatlarini aniqlashga
imkon beradi. Kasallikning tarqalishida aholi hududiy taqsimlanishning o’rni yuqori
ekanligini oxirgi paytlarda butun dunyo bo’ylab sayohat qilish imkoniyatlarining
qulayligi va turli xil sayohat imkoniyatlarining mavjudligi bilan bog’lash mumkin.
Ayni ana shu sabab dunyo bo’ylab kasallikning yangi shtammlarini tez fursatda
tarqalishiga imkon berdi. Shunday qilib, tarqalib borayotgan SARS-CoV-2
infeksiyasi ko'pincha statistik ma’lumotlarni tartiblash salohiyatiga ega bo'lgan yuqori
resursli sharoitlarda aniqlansada, ularning kelib chiqishi to’liqligicha aniqlanmagan.
Virusga bog’liq bo’lgan ma’lumotlarni nazorat qilishni yanada murakkablashtiradigan
narsa qishloq aholisi orasida tizimli statistik kuzatuvning mavjud emasligi bo’lib
hisoblanadi .
References
Foydalanilgan adabiyotlar:
1. Curtin SC, Spencer MR. Trends in death rates in urban and rural areas: United
States, 1999–2019. NCHS Data Brief, no 417. Hyattsville, MD: National Center for
Health Statistics. 2021. DOI: https://dx.doi.org/10.15620/cdc:109049.
2. Xu JQ, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2020.
NCHS Data Brief, no 427. Hyattsville, MD: National Center for Health Statistics.
2021. DOI: https://dx.doi.org/ 10.15620/cdc:112079.
3. Ingram DD, Franco SJ. 2013 NCHS urban–rural classification scheme for counties.
National Center for Health Statistics. Vital Health Stat 2(166). 2014.
4. Ullrich F, Mueller K. COVID-19 Cases and deaths, metropolitan and
nonmetropolitan counties over time (update). Iowa City, IA: RUPRI Center for
Rural Health Policy Analysis. 2022. Available from: https://rupri.public-
health.uiowa.edu/publications/policybriefs/2020/
COVID%20Longitudinal%20Data.pdf.
5. Centers for Disease Control and Prevention. CDC WONDER. About underlying
cause of death, 1999–2020. 2022. Available from: https://wonder.cdc.gov/ucd-
icd10.html.
6. Murphy SL, Xu JQ, Kochannek KD. Arias E. Deaths: Final data for 2019. National
Vital Statistics Reports; vol 70 no 8. Hyattsville, MD: National Center for Health
Statistics. 2021. DOI: https://dx.doi.org/10.15620/cdc:106058.
7. World Health Organization. International statistical classification of diseases and
related health problems, 10th revision. 2008 ed. 2009
8. Davies Nicholas, G. et al. Estimated transmissibility and impact of SARS-CoV- 2
lineage B.1.1.7 in England. Science 372, eabg3055 (2021).
9. Allen H. et al. Household transmission of COVID-19 cases associated with SARS
CoV-2 delta variant (B.1.617.2): national case-control study. The Lancet Regional
Health – Europe.
10. Meo, S. A., Meo, A. S., Al-Jassir, F. F. & Klonoff, D. C. Omicron SARS-CoV-2
new variant: global prevalence and biological and clinical characteristics. Eur. Rev.
Med. Pharmacol. Sci. 25, 8012–8018 (2021).
11. Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants
to neutralizing antibodies. Nat. Med. 27, 917–924 (2021).
12. Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against
the B.1.351 Variant. N. Engl. J. Med. 384, 1885–1898 (2021).
13. Jangra, S. et al. SARS-CoV-2 spike E484K mutation reduces antibody
neutralisation. Lancet Microbe 2, e283–e284 (2021).
14. Chia P. Y. et al. Virological and serological kinetics of SARS-CoV-2 Delta variant
vaccine-breakthrough infections: a multi-center cohort study. 2021:
2021.07.28.21261295
15. Araf, Y. et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and
responses to current COVID-19 vaccines. J. Med. Virol. 94, 1825–1832 (2022).
16. SARS-CoV-2 variants of concern as of 4 August 2022. August 5, 2022. https://
www.ecdc.europa.eu/en/covid-19/variants-concern (accessed August 9, 2022
